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Abstract 
Background: The intensely increasing multi-drug resistant microbial infections have encouraged the search for new 
antimicrobial agents. Hydrazone derivatives are known to exhibit a wide variety of biological activities including anti-
microbial. In heterocyclic moiety, imidazo[1,2-a]pyrimidines are the subject of immense interest for their antimicrobial 
activity and also for their analgesic, antipyretic and anti-inflammatory properties.
Results: Condensation of 5,6,7,8-tetrahydroimidazo[1,2-a]pyrimidine-2-carbohydrazide 7 with aromatic aldehydes 
a–k in ethanol at reflux led to the generation of hydrazone derivatives 8a–k in 80–92% yield. The synthesis of car-
bohydrazide 7 was accomplished in six steps from commercially available 2-amino pyrimidine. The structures of the 
synthesized compounds were confirmed by 1H, 13C NMR, Mass and IR spectral data. All the synthesized hydrazone 
derivatives 8a–k were tested in vitro for their antibacterial activity. Compounds 8d, 8e and 8f exhibited excellent 
antibacterial activity with zone of inhibition 30–33 mm against E. coli (Gram negative bacteria) and S. aureus (Gram 
positive bacteria). These compounds also exhibited excellent antibacterial activity with zone of inhibition 22–25 mm 
against P. aeruginosa (Gram negative bacteria) and S. pyogenes (Gram positive bacteria).
Conclusion: Synthesized and recorded antibacterial activity of some new 5,6,7,8-tetrahydro-imidazo[1,2-a]pyrimi-
dine-hydrazone derivatives.
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Background
The fast resistance of bacteria against antibiotics has 
become a prevailing medical problem. Treatment options 
for these infections are often inadequate especially in 
immune compromised patients. The intensely increasing 
multi-drug resistant microbial infections in the past few 
decades have become a serious health issue. The explora-
tion of new antimicrobial agents will always remain as a 
major challenging task.
Hydrazones constitute a versatile compound of organic 
class having the basic structure R1R2C=NNH2. Hydra-
zones are formed by the replacement of the oxygen of 
carbonyl compounds with the –NNH2 functional group. 
The α-hydrogen atom of hydrazones is more acidic 
as compared to ketones [1, 2], because of its nucleo-
philic nature. Hydrazones are mainly synthesized by 
refluxing the appropriate quantity of substituted hydra-
zines/hydrazides with ketones and aldehydes in suit-
able solvents like ethanol, ethanol-glacial acetic acid, 
tetrahydrofuran, butanol, methanol, glacial acetic acid, 
etc. Hydrazone is a moiety that exhibits a wide variety of 
biological activities like anticonvulsant, antidepressant, 
analgesic, antimicrobial, antitumor, anti-platelet, vasodi-
lator, antiviral, anticancer, antitubercular and anti-HIV 
[3–10].
Imidazo[1,2-a]pyrimidines are evolving as potentially 
interesting drugs particularly with regard to their antimi-
crobial, analgesic, antipyretic, anti-inflammatory proper-
ties and also with regard to their activity against ulcers 
[13]. They are also important as benzodiazepine receptor 
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agonists, antiviral agents and calcium channel blockers 
[14].
Keeping in view of the biological importance of 
hydrazones and Imidazo[1,2-a]pyrimidines, in con-
tinuation to our research program about a potent 
antimicrobial agent, we report herein the synthesis, 
characterization and antibacterial activity of some new 
5,6,7,8-tetrahydro-imidazo[1,2-a]pyrimidine-hydra-
zone derivatives. It is interesting to note that, a class of 
5,6,7,8-tetrahydroimidazo[1,2-a]pyrimidine compounds 
is prescribed for treatment to reduce neurotoxic injury 
associated with anoxia or ischemia which typically fol-




The synthesis of 5,6,7,8-tetrahydro-imidazo[1,2-a]pyrimi-
dine-hydrazone derivatives 8a–k described in this paper 
were prepared according to the synthetic Scheme  1. 
The cyclo condensation reactions of 1,1,3-trichloro 
acetone with 2-aminopyrimidine 1 to 2-(dichlorome-
thyl)imidazo[1,2-a]pyrimidine 2 was carried out in 
ethanol at reflux temperature for 10  h. Dichloromethyl 
imidazo[1,2-a]pyrimidine 2 was treated with CaCO3 
in water at reflux for 1  h to produce imidazo[1,2-a]
pyrimidine-2-carbaldehyde 3. The oxidation of alde-
hyde 3 was carried out in presence of oxone to obtain 
the desired imidazo[1,2-a]pyrimidine-2-carboxylic acid 
4. Esterification of carboxylic acid 3 followed by the 
hydrogenation in presence of PtO2 at 30 psi resulted in 
the formation of ethyl 5,6,7,8-tetrahydroimidazo[1,2-
a]pyrimidine-2-carboxylate 6. Treatment of com-
pound 6 with hydrazine-hydrate in ethanol at reflux 
temperature enabled in forming the key intermediate 
5,6,7,8-tetrahydroimidazo[1,2-a]pyrimidine-2-carbohy-
drazide 7. Condensation of carbohydrazide 7 with vari-
ous aromatic aldehydes a–k in ethanol at reflux led to 
the generation of hydrazone derivatives 8a–k in 80–92% 
yield (Scheme 1). The structures of the synthesized com-
pounds were confirmed by 1H NMR, Mass and IR spectral 
data. As a representative example, the 1H NMR spec-
tra of (E-N′-(4-(trifluoromethyl)benzylidene)-5,6,7,8-
tetrahydroimidazo[1,2-a]pyrimidine-2-carbohydrazide 8d 
is characterized as follows: the four singlets at 11.26, 8.52, 
7.36 and 6.32  ppm with one proton integration corre-
sponds to –CO–NH–N–, –N=HC–Ar, Imidazo-HC=C– 
and –CH2–NH– groups, respectively. The doublet signals 
at 7.85 and 7.78  ppm with two proton integration rep-
resents to 4-CF3 aromatic ring. The broad singlets with 
two proton integrations at 3.94, 3.35 and 1.95  ppm cor-
responds to the cyclic 5,6,7,8-tetrahydroimidazo ring. 
The mass spectra of the synthesized compounds showed 
(M+H) peaks, in agreement with their molecular for-
mula. The IR data provided functional group evidence for 










































8a. R = 4-F; 8b. R = 2-CF3; 8c. R = 3-CF3; 8d. R = 4-CF3; 8e. R = 4-OCF3; 8f. R = 4-OCHF2;
8g. R = 2,4-difluoro; 8h. R = 3,4-difluoro; 8i. R = 2-Me, 3-F; 8j. R = 2-Cl,3-F; 8k. R = benzo[b]furan
Scheme 1 Synthesis of 5,6,7,8-tetrahydro-imidazo [1,2-a]pyrimidine-hydrazone derivatives 8a–k. Reagents and conditions: a 1,1,3-trichloro 
acetone, NaHCO3, EtOH, reflux, 10 h; b CaCO3, water, reflux, 1 h; c oxone, DMF, 5°C, 2 h; d Conc; H2SO4, ethanol, reflux, 16 h; e 10% Pd–C, Ethanol, H2, 
30 psi, 3 h; f hydrazine hydrate, Ethanol, reflux, 6 h; g benzaldehydes a–k, ethanol, reflux, 6 h.
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8a–k were dissolved in dimethylsulphoxide at 250  μg/
mL concentration (standard antibacterial drug, Nor-
floxacin was used as the reference antibiotic) and tested 
against Gram negative strains of (1) Escherichia coli 
(MTCC 443), (2) Pseudomonas aeruginosa (MTCC 424) 
and Gram positive strains of (3) Staphylococcus aureus 
(MTCC 96) and (4) Streptococcus pyogenes (MTCC 442) 
using agar well diffusion method according to the litera-
ture protocol [12, 13]. Activity was determined by zones 
showing complete inhibition (mm). Growth inhibition 
was calculated with reference to positive control. All the 
samples were taken in triplicates.
Antibacterial activity
The screening results of antibacterial activity of hydra-
zone derivatives 8a–k are summarized in Table  1. It 
is observed that compounds 8d, 8e and 8f revealed 
excellent antibacterial activity with zone of inhibition 
30–33 mm against E. coli (Gram negative bacteria) and S. 
aureus (Gram positive bacteria) even in the case of P. aer-
uginosa (Gram negative bacteria) and S. pyogenes (Gram 
positive bacteria), compounds 8d, 8e and 8f displayed 
excellent anti-bacterial activity with zone of inhibition 
22–25 mm. Compounds 8a, 8b and 8c showed appreci-
able activity while the compounds 8g and 8h showed 
moderate activity against all the tested bacterial strains. 
From the structural point of view of the scaffold, it may 
be generalized that scaffold with R  =  4-CF3, 4-OCF3 
and 4-OCHF2 showed excellent antibacterial activ-
ity, while R =  4-F, 2-CF3 and 3-CF3 showed good anti-
bacterial activity and R  =  2,4-difluoro and 3,4-difluoro 
showed moderate antibacterial activity. Furthermore, 
it is observed that within the series of the hydrazone 
derivatives 8a–k, compounds 8i (R  =  2-Me, 3-F), 8j 
(R =  2-Cl, 3-F) and 8k (R =  benzo[b]furan) showed no 
activity.
Experimental section
All commercial chemicals were taken as they are. The 
solvents underwent purification process as per standard 
procedures. For thin-layer chromatography (TLC) anal-
ysis, Merck pre-coated Plates (silica gel 60 F254) were 
used and spots were visualized with UV light. Merck 
silica gel 60 (230–400 mesh) was used for flash column 
chromatography and the eluting solvents were indicated 
in the procedures. Melting point (mp) determinations 
were performed by using Mel-temp apparatus and are 
uncorrected. 1H NMR spectra were recorded in Varian 
MR-400 MHz instrument. Chemical shifts were reported 
in δ parts per million (ppm) downfield from tetramethyl-
silane (TMS) with reference to internal standard and 
the signals were reported as s (singlet), d (doublet), dd 
(doublet of doublet), t (triplet), q (quartet), m (multiplet) 
and coupling constants in Hz. The mass spectra were 
recorded on Agilent ion trap MS. Infrared (IR) spectra 
were recorded on a Perkin Elmer FT-IR spectrometer. 
The benzaldehydes a–k utilized for the synthesis of 8a–k 
were purchased from commercial sources.
Synthesis of 2‑(dichloromethyl)imidazo[1,2‑a]pyrimidine 2
To a mixture of 2-aminopyrimidine (5  g, 52.57  mmol), 
sodium bicarbonate (11.34 g, 105.14 mmol) in ethylalco-
hol (20 mL) was added 1,1,3-trichloro acetone (12.70 g, 
78.85 mmol) and stirred at reflux for 10 h. The comple-
tion of the reaction was monitored by TLC, the reaction 
mixture was poured into ice-water (30 mL) with vigorous 
Table 1 Antibacterial activity of compounds 8a–k (concentration used 250 μg/mL of DMSO)
Compound no. Zones of inhibition of compounds 8a–k in mm
Gram negative Gram positive
E. coli MTCC 443 P. aeruginosa MTCC 424 S. aureus MTCC 96 S. pyogenes MTCC 442
8a 25 19 24 17
8b 27 20 23 18
8c 26 19 23 17
8d 33 24 29 24
8e 30 25 30 22
8f 30 23 31 22
8g 20 16 19 13
8h 21 15 19 14
8i – – – –
8j – – – –
8k – – – –
Standard drug: Norfloxacin 29 23 28 21
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stirring to precipitate the product, 2-(dichloromethyl)
imidazo[1,2-a]pyrimidine 2. The crude compound was 
taken to the next step without further purification.
Synthesis of imidazo[1,2‑a]pyrimidine‑2‑carbaldehyde 3
The compound 2 (1 g, 4.95 mmol) was dissolved in water 
(30  mL) and CaCO3 was added (5  g, 24.75  mmol) and 
refluxed for 1 h. The reaction mixture was cooled to room 
temperature and extracted with ethylacetate and evapo-
rated under reduced pressure to obtain the crude com-
pound 3, which was purified by column chromatography 
(silica gel: 60–120 mesh, eluent: 1% MeOH/CHCl3) to 
afford compound 3. Pale yellow solid, Yield: 60%; M.p: 209–
210°C. 1H NMR (400 MHz, CDCl3): δ 9.96 (s, 1H), 9.66 (q, 
J = 6.8 Hz, 1H), 8.88 (q, J = 4.0 Hz, 1 H), 8.70 (s, 1H), 7.43 
(q, J = 6.4 Hz, 1 H). ESI–MS: m/z, 148.2 (M+H)+.
Synthesis of imidazo[1,2‑a]pyrimidine‑2‑carboxylic acid 4
To a solution of compound 3 (2 g, 13.60 mmol) in DMF 
(15 vol), Oxone was added (40.80 mmol) at 5°C and stirred 
for 2 h. The completion of the reaction was monitored by 
TLC. As soon as the reaction was completed, the reaction 
mixture was diluted with water (45 mL) followed by ethyl 
acetate. The organic layer was washed with water followed 
by brine solution, dried over sodium sulphate, filtered and 
evaporated to produce compound 4 as pale yellow syrupy 
liquid. The crude compound was used in the next step 
without further purification. Yield: 1.10 g, 50%.
Synthesis of ethyl imidazo[1,2‑a]  
pyrimidine‑2‑carboxylate 5
To a solution of compound 4 (1.10  g, 6.75  mmol) in 
ethanol (12 mL), Conc. H2SO4 (catalyst) was added and 
refluxed for 16  h. The reaction mixture was evaporated 
and the residue was extracted with EtOAc (2 × 15 mL). 
The organic layer was washed with water followed by 
brine solution, dried over anhydrous sodium sulphate, 
filtered and evaporated to isolate compound 5 as a yel-
low viscous liquid. Yield: 1.06  g, 85%. M.p. 180–183°C; 
1H NMR (400 MHz, CDCl3): δ 8.66 (dd, J = 2.1, 3.9 Hz, 
1H), 9.50 (dd, J = 1.8, 6.9 Hz, 1H), 8.15 (s, 1H), 6.96 (dd, 
J  =  4.2, 6.9  Hz, 1H), 4.45 (q, J  =  7.2  Hz, 2H), 1.44 (t, 
J = 7.2 Hz, 3H). ESI–MS: m/z, 192.0 (M+H)+
Synthesis of ethyl 5,6,7,8‑tetrahydroimidazo[1,2‑a]
pyrimidine‑2‑carboxylate 6
A solution of compound 5 (1.06 g, 5.55 mmol) in ethanol 
(20 mL): conc. HCl (0.5 mL) was hydrogenated at 30 psi 
in the presence of 20% PtO2 (200 mg) for 3 h. The reac-
tion mixture was filtered under nitrogen atmosphere 
and the filtrate was evaporated to obtain compound 6. 
The pH of the solution was adjusted to 9–10 with aque-
ous sodium carbonate solution and extracted with 
chloroform (2 × 25 mL). The combined organic extracts 
were washed with water (50 mL) followed by brine solu-
tion. The organic layer was dried over anhydrous sodium 
sulphate and concentrated in vacuum to isolate com-
pound 6 as yellow solid. Yield: 0.97  g, 90%; M.p: 170–
171°C; 1H NMR (400 MHz, CDCl3): δ 7.18 (s, 1H), 6.25 
(brs, 1H), 1.36 (t, J = 7.2 Hz, 3H), 2.07 (t, J = 5.7 Hz, 2H), 
3.45 (t, J = 5.4 Hz, 2H), 3.90 (t, J = 6.0 Hz, 2H), 4.32 (q, 
J = 7.2 Hz, 2H), ESI–MS: m/z, 196.2 (M+H)+.
Synthesis of 5,6,7,8‑tetrahydroimidazo[1,2‑a]
pyrimidine‑2‑carbohydrazide 7
A mixture of compound 6 (0.95 g, 4.87 mmol) and hydra-
zine hydrate (5.0 mmol) in ethanol (4 mL) was refluxed 
for 6 h. The reaction mixture was evaporated and the res-
idue was diluted with EtOAc and water. The organic layer 
was washed with water followed by brine solution, sepa-
rated, dried over anhydrous Na2SO4, filtered and evapo-
rated to obtain compound 7 as a pale yellow solid. Yield: 
80%; M.p: 116–117°C; 1H NMR (400 MHz, CDCl3): δ 8.50 
(s, 1H), 7.09 (s, 1H), 6.34 (s, 1H), 4.20 (brs, 1H), 3.86 (t, 
J =  6.0  Hz, 2H), 3.21–3.17 (m, 2H), 1.93–1.87 (m, 2H); 
ESI–MS: m/z, 181.8 (M+H)+.
General experimental procedure for the synthesis 
of hydrazone derivatives (8a–k)
Respective benzaldehydes a–k (1.0 mmol) were added to 
an ethanol solution containing 7(100  mg, 0.553  mmol) 
and the contents were stirred at reflux temperature for 
6  h. Ethanol was evaporated from the reaction mixture 
and the residue was extracted with pet-ether, to obtain 




M.p: 84–85°C; IR(KBr): υmax 3,443, 3,303, 3,275, 3,243, 
3,187, 2,981, 1,667, 1,612, 1,602, 1,565, 1,506, 1,495, 
1,425, 1,415, 1,370, 1,350, 1,319, 1,290, 1,275, 1,236, 
1,209, 1,192, 1,183, 1,156, 1,135, 1,112, 1,101, 1,064, 998, 
959, 930, 901, 854, 837, 819, 788, 751, 629, 612, 566, 519, 
505  cm−1; 1H NMR (400  MHz, DMSO-d6): δ 11.01 (s, 
1H), 8.43 (s, 1H), 7.71–7.68 (m, 2H), 7.32–7.25 (m, 3H), 
6.30 (s, 1H), 3.39 (t, J = 5.6 Hz, 2H), 3.24 (brm, 2H), 1.94 
(t, J = 5.6 Hz, 2H); ESI–MS: m/z, 287.9 (M+H)+.
(E)‑N′‑(2‑(trifluoromethyl) benzylidene)‑5,6,7,8‑tetrahydroim
idazo[1,2‑a]pyrimidine‑2‑carbohydrazide (8b)
M.p: 104–105°C; 1H NMR (400 MHz, DMSO-d6): δ 11.22 
(s, 1H), 8.86 (s, 1H), 8.16 (d, J  =  8.4  Hz, 1H), 7.76 (d, 
J = 8.4 Hz, 1H), 7.74–7.59 (m, 2H), 7.35 (s, 1H), 6.28 (s, 
1H), 3.93 (brs, 2H), 3.24 (brs, 2H), 1.94 (brs, 2H); ESI–
MS: m/z, 337.9 (M+H)+.
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(E)‑N’‑(3‑(trifluoromethyl)benzylidene)‑5,6,7,8‑tetrahydroimi
dazo[1,2‑a]pyrimidine‑2‑carbohydrazide (8c)
M.p: 98–99°C; 1H NMR (400  MHz, DMSO-d6): δ 11.22 
(s, 1H), 8.86 (s, 1H), 8.16 (d, J  =  8.4  Hz, 1H), 7.76 (d, 
J = 8.4 Hz, 1H), 7.74–7.59 (m, 2H), 7.35 (s, 1H), 6.28 (s, 
1H), 3.93 (brs, 2H), 3.24 (brs, 2H), 1.94 (brs, 2H); ESI–
MS: m/z, 337.9 (M+H)+.
(E)‑N’‑(4‑(trifluoromethyl) benzylidene)‑5,6,7,8‑tetrahydroimi
dazo[1,2a]pyrimidine‑2‑carbohydrazide (8d)
M.p: 120–121°C; IR(KBr): υmax 3,443, 3,261, 3,242, 3,184, 
3,147, 3,131, 3,085, 3,011, 2,982, 2,959, 2,936, 2,851, 
2,206, 1,663, 1,625, 1,560, 1,522, 1,507, 1,494, 1,463, 
1,445, 1,433, 1,413, 1,364, 1,331, 1,321, 1,300, 1,293, 
1,271, 1,235, 1,210, 1,193, 1,182, 1,158, 1,134, 1,119, 
1,102, 1,068, 1,017, 994, 967, 959, 939, 898, 895, 842, 832, 
784, 762, 720, 709, 672, 644, 630, 615, 594, 508, 503 cm−1 
1H NMR (400 MHz, DMSO-d6): δ 11.26 (s, 1H), 8.52 (s, 
1H), 7.85 (d, J = 8.4 Hz, 2H), 7.78 (d, J = 8.0 Hz, 2H), 7.36 
(s, 1H), 6.32 (s, 1H), 3.94 (brs, 2H), 3.35 (brs, 2H), 1.95 
(brs, 2H); ESI–MS: m/z, 337.8 (M+H)+.
(E)‑N′‑(4‑(trifluoromethoxy)benzylidene)‑5,6,7,8‑tetrahydro 
imidazo[1,2‑a]pyrimidine‑2‑carbohydrazide (8e)
M.p: 126–127°C; IR(KBr): υmax 3,243, 3,224, 3,182, 3,099, 
3,054, 2,972, 2,883, 2,847, 1,653, 1,631, 1,605, 1,555, 
1,535, 1,506, 1,492, 1,441, 1,414, 1,386, 1,367, 1,351, 
1,325, 1,301, 1,270, 1,243, 1,217, 1,193, 1,166, 1,099, 
1,090, 1,072, 1,017, 1,002, 964, 944, 918, 902, 878, 850, 
793, 756, 715, 677, 650, 662, 600, 532  cm−1; 1H NMR 
(400 MHz, DMSO-d6): δ 11.10 (s, 1H), 8.46 (s, 1H), 7.76 
(d, J = 8.4 Hz, 2H), 7.42 (d, J = 8.4 Hz, 2H), 7.33 (s, 1H), 
6.30 (s, 1H), 3.92 (t, J = 6.0 Hz, 2H), 3.24 (brs, 2H), 1.94 
(brs, 2H); ESI–MS: m/z, 354.0 (M+H)+.
(E)‑N′‑(4‑(difluoromethoxy)benzylidene)‑5,6,7,8‑tetrahydro 
imidazo[1,2‑a]pyrimidine‑2‑carbohydrazide (8f)
M.p: 119–120°C; IR(KBr): υmax 3,429, 3,272, 3,099, 3,056, 
3,041, 2,972, 2,920, 2,886, 2,847, 1,644, 1,603, 1,575, 
1,538, 1,508, 1,456, 1,440, 1,417, 1,372, 1,323, 1,295, 
1,278, 1,231, 1,214, 1,203, 1,189, 1,174, 1,124, 1,115, 
1,100, 1,023, 961, 936, 903, 864, 836, 789, 717, 702, 679, 
647, 617, 582, 561, 529, 492, 479, 459  cm−1; 1H NMR 
(400 MHz, DMSO-d6): δ 11.02 (s, 1H), 8.43 (s, 1H), 7.70 
(d, J = 8.8 Hz, 2H), 7.31 (s, 1H), 7.22 (d, J = 8.4 Hz, 2H), 
6.30 (s, 1H), 3.92 (t, J = 5.6 Hz, 2H), 3.24 (brs, 2H), 1.94 
(t, J = 5.8 Hz, 2H); ESI–MS: m/z, 336.0 (M+H)+.
(E)‑N′‑(2,4‑difluorobenzylidene)‑5,6,7,8‑tetrahydroimidazo 
[1,2‑a]pyrimidine‑2‑carbohydrazide (8 g)
M.p: 138–139°C; IR(KBr): υmax 3,429, 3,265, 3,193, 3,139, 
3,120, 3,097, 3,008, 2,981, 2,962, 2,882, 2,562, 1,665, 
1,617, 1,561, 1,517, 1,492, 1,459, 1,427, 1,372, 1,316, 
1,282, 1,214, 1,190, 1,175, 1,140, 1,097, 1,066, 995, 945, 
897, 854, 828, 820, 782, 744, 728, 718, 707, 638, 629, 610, 
577, 542, 509; cm−1; 1HNMR (400  MHz, DMSO-d6): 
δ 11.32 (s, 1H), 8.64 (s, 1H), 7.96–7.90 (m, 1H), 7.35 (d, 
J = 2.8 Hz, 1H), 7.18 (t, J = 8.8 Hz, 1H), 6.27 (s, 1H), 3.92 
(t, J = 6.0 Hz, 2H), 3.24 (brs, 2H), 1.94 (t, J = 5.2 Hz, 2H); 
ESI–MS: m/z, 305.0 (M+H)+.
(E)‑N′‑(3,4‑difluorobenzylidene)‑5,6,7,8‑tetrahydroimidazo 
[1,2‑a]pyrimidine‑2‑carbohydrazide (8h)
M.p: 143–144°C; IR(KBr): υmax 3,415, 3,307, 3,249, 3,114, 
2,884, 2,559, 1,672, 1,617, 1,513, 1,437, 1,423, 1,370, 
1,301, 1,283, 1,231, 1,205, 1,137, 1,110, 1,083, 988, 937, 
918, 889, 876, 796, 767, 716, 636, 578, 537, 515 cm−1; 1H 
NMR (400 MHz, DMSO-d6): δ 11.30 (s, 1H), 8.48 (s, 1H), 
7.88 (s, 1H), 7.68-7.19 (m, 3H), 6.30 (s, 1H), 3.93 (brs, 




M.p: 81–82°C; IR(KBr): υmax 3,419, 3,170, 3,097, 3,060, 
2,967, 2,906, 2,835, 1,650, 1,633, 1,594, 1,556, 1,492, 
1,456, 1,442, 1,417, 1,391, 1,379, 1,368, 1,352, 1,324, 1,300, 
1,266, 1,238, 1,225, 1,194, 1,152, 1,099, 1,067, 1,004, 992, 
962, 955, 896, 826, 811, 717, 698, 617, 577, 517 cm−1; 1H 
NMR (400 MHz, DMSO-d6): δ 11.00 (s, 1H), 8.72 (s, 1H), 
7.86 (d, J = 8.4 Hz, 1H), 7.30 (s, 1H), 7.10-7.05 (m, 2H), 
6.28 (s, 1H), 3.92 (t, J = 5.6 Hz, 2H), 3.24 (brs, 2H), 1.94 
(brs, 2H); ESI–MS: m/z, 302.10 (M+H)+.
(E)‑N′‑(2‑chloro‑3‑(trifluoromethyl)benzylidene)‑5,6,7,8‑tetra
hydroimidazo[1,2‑a]pyrimidine‑2‑carbohydrazide (8j)
M.p: 117–119°C; 1H NMR (400 MHz, DMSO-d6): δ 11.58 
(s, 1H), 8.88 (s, 1H), 8.20 (d, J  =  8.4  Hz, 1H), 7.88 (d, 
J = 8.6 Hz, 1H), 7.58 (t, J = 7.8 Hz, 1H), 7.30 (s, 1H), 6.25 
(s, 1H), 3.94 (t, J =  5.8  Hz, 2H), 3.22 (brs, 2H), 1.94 (t, 
J = 5.4 Hz, 2H); ESI–MS: m/z, 372.13 (M+H)+.
(E)‑N′‑((benzofuran‑2‑yl)methylene)‑5,6,7,8‑tetrahydroimida
zo[1,2‑a]pyrimidine‑2‑carbohydrazide (8k)
M.p: 117–119°C; IR(KBr): υmax 3,366, 3,239, 3,135, 2,964, 
2,930, 2,881, 1,659, 1,607, 1,574, 1,560, 1,506, 1,492, 
1,474, 1,448, 1,406, 1,366, 1,331, 1,317, 1,290, 1,242, 
1,219, 1,196, 1,158, 1,144, 1,131, 1,106, 1,095, 1,073, 
1,004, 992, 952, 943, 891, 873, 839, 824, 764, 715, 659, 
613, 580, 544, 468, 459, 440  cm−1; 1H NMR (400  MHz, 
DMSO-d6): δ 11.30 (s, 1H), 8.50 (s, 1H), 7.60–7.48 (m, 
2H), 7.32–7.28 (m, 1H), 7.18 (s, 1H), 6.30 (s, 1H), 3.94 (t, 
J = 5.8 Hz, 2H), 3.40 (brs, 2H), 1.80 (brs, 2H); ESI–MS: 
m/z, 310.14 (M+H)+.
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Conclusion
The synthesis of 5,6,7,8-tetrahydro-imidazo[1,2-a]
pyrimidine-hydrazone derivatives 8a–k described in this 
paper was prepared in six elaborate steps from commer-
cially available 2-aminopyrimidine as starting material. 
All the synthesised compounds 8a–k were investigated 
for their in  vitro antimicrobial activity. Compounds 8d, 
8e and 8f demonstrated excellent antibacterial activity 
with zone of inhibition 30–33 mm against E. coli (Gram 
negative bacteria) and S. aureus (Gram positive bacte-
ria) These compounds also displayed excellent antibac-
terial activity with zone of inhibition 22–25 mm even in 
the case of P. aeruginosa(Gram negative bacteria) and S. 
pyogenes(Gram positive bacteria).
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